Tags

Type your tag names separated by a space and hit enter

Real-life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites.
Dermatol Ther. 2019 11; 32(6):e13093.DT

Abstract

Ivermectin is a drug approved for the treatment of papulopustular rosacea (PPR). Although clinical guidelines recommend the use of ivermectin as the first-line treatment in patients with almost clear and mild rosacea, studies concerning its use on them are lacking. This study investigated the effectiveness and the tolerability of ivermectin in almost clear to severe rosacea and assessed the antiparasitic effect on Demodex mites. This is a retrospective study based on 50 patients affected by PPR and treated with topical ivermectin 1% once daily over 16 weeks. The disease severity, the patient-examined improvement, and the safety assessment of patients were evaluated. Demodex mites were studied with the standardized skin surface biopsy. PPR to all severity achieved a therapeutic success. The number of inflammatory lesions was significantly decreased in almost clear (p < .0001), mild, moderate, and severe (p < .001) forms. A complete remission of inflammatory lesions was achieved by almost clear (p < .001) and mild (p = .005) with 82% with none-to-mild cutaneous adverse events. Thirty-two percent were positive for Demodex mites, and all of them turned negative after 16 weeks. Ivermectin is an effective treatment not only in moderate to severe PPR but also in almost clear/mild rosacea.

Authors+Show Affiliations

Section of Dermatology, Department of Health Science, University of Genoa, Genoa, Italy.Section of Dermatology, Department of Health Science, University of Genoa, Genoa, Italy.Section of Dermatology, Department of Health Science, University of Genoa, Genoa, Italy.Section of Dermatology, Department of Health Science, University of Genoa, Genoa, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31579993

Citation

Trave, Ilaria, et al. "Real-life Experience On Effectiveness and Tolerability of Topical Ivermectin in Papulopustular Rosacea and Antiparasitic Effect On Demodex Mites." Dermatologic Therapy, vol. 32, no. 6, 2019, pp. e13093.
Trave I, Merlo G, Cozzani E, et al. Real-life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites. Dermatol Ther. 2019;32(6):e13093.
Trave, I., Merlo, G., Cozzani, E., & Parodi, A. (2019). Real-life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites. Dermatologic Therapy, 32(6), e13093. https://doi.org/10.1111/dth.13093
Trave I, et al. Real-life Experience On Effectiveness and Tolerability of Topical Ivermectin in Papulopustular Rosacea and Antiparasitic Effect On Demodex Mites. Dermatol Ther. 2019;32(6):e13093. PubMed PMID: 31579993.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Real-life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites. AU - Trave,Ilaria, AU - Merlo,Giulia, AU - Cozzani,Emanuele, AU - Parodi,Aurora, Y1 - 2019/10/30/ PY - 2019/08/08/received PY - 2019/09/11/revised PY - 2019/09/20/accepted PY - 2019/10/4/pubmed PY - 2020/5/19/medline PY - 2019/10/4/entrez KW - Demodex density KW - ivermectin KW - papulopustular rosacea SP - e13093 EP - e13093 JF - Dermatologic therapy JO - Dermatol Ther VL - 32 IS - 6 N2 - Ivermectin is a drug approved for the treatment of papulopustular rosacea (PPR). Although clinical guidelines recommend the use of ivermectin as the first-line treatment in patients with almost clear and mild rosacea, studies concerning its use on them are lacking. This study investigated the effectiveness and the tolerability of ivermectin in almost clear to severe rosacea and assessed the antiparasitic effect on Demodex mites. This is a retrospective study based on 50 patients affected by PPR and treated with topical ivermectin 1% once daily over 16 weeks. The disease severity, the patient-examined improvement, and the safety assessment of patients were evaluated. Demodex mites were studied with the standardized skin surface biopsy. PPR to all severity achieved a therapeutic success. The number of inflammatory lesions was significantly decreased in almost clear (p < .0001), mild, moderate, and severe (p < .001) forms. A complete remission of inflammatory lesions was achieved by almost clear (p < .001) and mild (p = .005) with 82% with none-to-mild cutaneous adverse events. Thirty-two percent were positive for Demodex mites, and all of them turned negative after 16 weeks. Ivermectin is an effective treatment not only in moderate to severe PPR but also in almost clear/mild rosacea. SN - 1529-8019 UR - https://brain.unboundmedicine.com/medline/citation/31579993/Real_life_experience_on_effectiveness_and_tolerability_of_topical_ivermectin_in_papulopustular_rosacea_and_antiparasitic_effect_on_Demodex_mites_ L2 - https://doi.org/10.1111/dth.13093 DB - PRIME DP - Unbound Medicine ER -